Supplementary Material and Methods

Sample preparation for xenotransplantation assays
For primary samples with blast counts <95% or for isolation of human AML cells from murine organs for secondary transplantations, enrichment using the MACS technology (Miltenyi, Bergisch-Gladbach, Germany) for CD33 (in 13/14 of samples) or CD38 (1/14) was performed. Post-MACS purities exceeded 95% (not shown).
Flow cytometric cell sorting of patient samples
For three patients, leukemic blasts were separated by flow cytometric cell sorting into CD34+ and CD34-cells using a FACS Aria III (BD Biosciences, Franklin Lakes, NJ, USA). Post-sort purities exceeded 95% (not shown).
Histopathology
For histopathological analyses, murine organs were fixed in 4% phosphate buffered formalin and then embedded in paraffin. Immunohistochemical analysis was performed as previously described (1), using H&E staining and 
Limiting dilution and homing assays
Limiting dilution assays were accomplished by transplanting 1 x 10 6 , 0.5 x 10 6 and 0.1 x 10 6 cells intravenously, and LSC frequencies then calculated using 
Next generation sequencing
NGS analysis was performed both on patient-derived AML cells and corresponding mouse-derived leukemic cells obtained by MACS purification of pooled BM samples from all engrafted animals transplanted with one AML.
DNA for NGS was isolated using ZR-Duet DNA/RNA MiniPrep kit (ZymoResearch, Irvine, CA, USA) according to the manufacturer's protocol and NGS analysis performed as previously described (2) . Patient NGS libraries were prepared using the AML community panel from Thermo Fisher containing 19 genes frequently mutated in AML (see ampliseq.com). Patient libraries were sequenced using the Ion PGM platform and analyzed using the Ion Reporter AML pipeline (version 5.0). The average coverage per sample was ~1.400-fold. Sensitivity for calling a mutation was set at 3%. If a mutation was observed in a "post-transplantation" sample but not reported to be present in the initial patient sample, the mapped reads were manually analyzed to assess whether the mutation was present but with a lower allelic burden than 3%. The sensitivity of such retrospective analysis is dependent on the coverage of the specific region (normally around 0.25%).
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